Association of irisin with fat mass, resting energy expenditure, and daily activity in conditions of extreme body mass index

International Journal of Endocrinology

Volumn 2014, Issue , 2014, Pages

  Pardo, María ^a,b   Crujeiras, Ana B ^a,b,c   Amil, María ^a,b   Aguera, Zaida ^b,d   Jiménez Murcia, Susana ^b,d,e   Baños, Rosa ^b,f   Botella, Cristina ^b,g   De La Torre, Rafael ^b,h   Estivill, Xavier ^i,j   Fagundo, Ana B ^b,d   Fernández Real, Jose M ^b,k   Fernández García, José C ^b,l   Fruhbeck, Gema ^b,m   Gómez Ambrosi, Javier ^b,m   Rodríguez, Roser ^b,k   Tinahones, Francisco J ^b,l   Fernández Aranda, Fernando ^b,d,e   Casanueva, Felipe F ^a,b  

^a Santiago University Clinical Hospital   (Spain)

^b Instituto de Salud Carlos III   (Spain)

^c BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e UNIVERSITY OF BARCELONA   (Spain)

^f UNIVERSITY OF VALENCIA   (Spain)

^g UNIVERSITAT JAUME I   (Spain)

^h HOSPITAL DEL MAR   (Spain)

ⁱ CENTRE FOR GENOMIC REGULATION CRG   (Spain)

^j CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^k GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

^l Department of Diabetes Endocrinology and Nutrition Hospital Cliínico Universitario Virgen de Victoria   (Spain)

^m UNIVERSITY CLINIC OF NAVARRA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FIBRONECTIN; IRISIN; UNCLASSIFIED DRUG;

ADULT; ANOREXIA NERVOSA; ARTICLE; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; FAT MASS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OBESITY; PHYSICAL ACTIVITY; PROTEIN BLOOD LEVEL; RESTING ENERGY EXPENDITURE;

EID: 84901048410     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2014/857270     Document Type: Article

References (40)

1. Villarejo C., Fernández-Aranda F., Jiménez-Murcia S., Peñas-Lledó E., Granero R., Penelo E., Tinahones F. J., Sancho C., Vilarrasa N., Montserrat-Gil de Bernabé M., Casanueva F. F., Fernández-Real J. M., Frühbeck G., de la Torre R., Treasure J., Botella C., Menchón J. M., Lifetime obesity in patients with eating disorders: increasing prevalence, clinical and personality correlates. European Eating Disorders Review 2012 20 3 250 254 2-s2.0-84859916407 10.1002/erv.2166
2. Treasure J., Cardi V., Kan C., Eating in eating disorders. European Eating Disorders Review 2012 20 1 e42 e49 2-s2.0-84855429456 10.1002/erv.1090
3. López M., Tovar S., Vázquez M. J., Williams L. M., Diéguez C., Peripheral tissue-brain interactions in the regulation of food intake. Proceedings of the Nutrition Society 2007 66 1 131 155 2-s2.0-34248200002 10.1017/S0029665107005368 (Pubitemid 46748251)
4. Pedersen B. K., Febbraio M. A., Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nature Reviews Endocrinology 2012 8 457 465 2-s2.0-84859095015 10.1038/nrendo.2012.49
5. Pardo M., Roca-Rivada A., Seoane L. M., Casanueva F. F., Obesidomics: contribution of adipose tissue secretome analysis to obesity research. Endocrine 2012 41 374 383 2-s2.0-84858331916 10.1007/s12020-012-9617-z
6. Pedersen B. K., The diseasome of physical inactivity-and the role of myokines in muscle-fat cross talk. The Journal of Physiology 2009 587 23 5559 5568 2-s2.0-71249157791 10.1113/jphysiol.2009.179515
7. Boström P., Wu J., Jedrychowski M. P., Korde A., Ye L., Lo J. C., Rasbach K. A., Boström E. A., Choi J. H., Long J. Z., Kajimura S., Zingaretti M. C., Vind B. F., Tu H., Cinti S., Højlund K., Gygi S. P., Spiegelman B. M., A PGC1- α -dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 2012 481 7382 463 468 2-s2.0-84856218208 10.1038/nature10777
8. Handschin C., Spiegelman B. M., The role of exercise and PGC1 α in inflammation and chronic disease. Nature 2008 454 7203 463 469 2-s2.0-47949104798 10.1038/nature07206
9. Cunha A., Basic research: irisin-behind the benefits of exercise. Nature Reviews Endocrinology 2012 8 4 195 2-s2.0-84858705567 10.1038/nrendo.2012.11
10. Sanchis-Gomar F., Lippi G., Mayero S., Perez-Quilis C., Garcia-Gimenez J. L., Irisin: a new potential hormonal target for treatment of obesity and type II diabetes. Journal of Diabetes 2012 4 196 10.1111/j.1753-0407.2012.00194.x
11. Villarroya F., Irisin, turning up the heat. Cell Metabolism 2012 15 3 277 278 2-s2.0-84858043988 10.1016/j.cmet.2012.02.010
12. Kelly D. P., Medicine: irisin, light my fire. Science 2012 335 6077 42 43 2-s2.0-84859507081 10.1126/science.1221688
13. Castillo-Quan J., From white to brown fat through the PGC-1alpha-dependent myokine irisin: implications for diabetes and obesity. Disease Models & Mechanisms 2012 5 293 295 10.1242/dmm.009894
14. Stengel A., Hofmann T., Goebel-Stengel M., Elbelt U., Kobelt P., Klapp B. F., Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity-correlation with body mass index. Peptides 2012 39 125 130
15. Huh J. Y., Panagiotou G., Mougios V., FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism: Clinical and Experimental 2012 61 1725 1738 10.1016/j.metabol.2012.09.002
16. Roca-Rivada A., Castelao C., Senin L. L., FNDC5/irisin is not only a myokine but also an adipokine. PLoS ONE 2013 8 e60563
17. Crujeiras A. B., Pardo M., Roca-Rivada A., Longitudinal variation of circulating irisin after an energy restriction-induced weight loss and following weight regain in obese men and women. American Journal of Human Biology 2014 26 2 198 207 10.1002/ajhb.22493
18. Moreno-Navarrete J. M., Ortega F., Serrano M., Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. The Journal of Clinical Endocrinology and Metabolism 2013 98 4 E769 E778 10.1210/jc.2012-2749
19. Hojlund K., Bostrom P., Irisin in obesity and type 2 diabetes. Journal of Diabetes and Its Complications 2013 27 303 304 10.1016/j.jdiacomp.2013.04.002
20. Association AP, APA, DSM-IV-TR Diagnostic and Statistical Manual of Mental Disorders 2000 American Psychiatric Association
21. First M. B., Donovan S., Frances A., Nosology of chronic mood disorders. Psychiatric Clinics of North America 1996 19 1 29 39 2-s2.0-0029960915 10.1016/S0193-953X(05)70271-9 (Pubitemid 26077726)
22. First M. B., Spitzer R., Gibbon M., Williams J., Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-Patient Edition (SCID-I/P) 2002 New York, NY, USA Biometrics Research, New York State Psychiatric Institute
23. Goldberg D. P., Manual of the General Health Questionnaire (GHQ-28) 1981 Toronto, Canada NFER Nelson
24. Strain G. W., Wang J., Gagner M., Pomp A., Inabnet W. B., Heymsfield S. B., Bioimpedance for severe obesity: comparing research methods for total body water and resting energy expenditure. Obesity 2008 16 8 1953 1956 2-s2.0-48749129365 10.1038/oby.2008.321
25. Routen A. C., Upton D., Edwards M. G., Peters D. M., Intra-and inter-instrument reliability of the actiwatch 4 accelerometer in a mechanical laboratory setting. Journal of Human Kinetics 2012 31 1 17 24 2-s2.0-84859404844 10.2478/v10078-012-0002-z
26. van der Pas S. C., Verbunt J. A., Breukelaar D. E., van Woerden R., Seelen H. A., Assessment of arm activity using triaxial accelerometry in patients with a stroke. Archives of Physical Medicine and Rehabilitation 2011 92 9 1437 1442 2-s2.0-80052222022 10.1016/j.apmr.2011.02.021
27. Matthews D. R., Hosker J. P., Rudenski A. S., Naylor B. A., Treacher D. F., Turner R. C., Homeostasis model assessment: insulin resistance and β -cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 7 412 419 2-s2.0-0021813187 (Pubitemid 15018832)
28. Mera R., Thompson H., Prasad C., How to calculate sample size for an experiment: a case-based description. Nutritional Neuroscience 1998 1 87 91
29. Crujeiras A. B., Zulet M. A., Lopez-Legarrea P., de la Iglesia R., Pardo M., Carreira M. C., Martínez J. A., Casanueva F. F., Association between circulating irisin levels and the promotion of insulin resistance during the weight maintenance period after a dietary weight-lowering program in obese patients. Metabolism: Clinical and Experimental 2014 63 4 520 531 10.1016/j.metabol.2013.12.007
30. de la Iglesia R., Lopez-Legarrea P., Crujeiras A. B., Pardo M., Casanueva F. F., Zulet M. A., Martinez J. A., Plasma irisin depletion under energy restriction is associated with improvements in lipid profile in metabolic syndrome patients. Clinical Endocrinology 2014 10.1111/cen.12383
31. Lopez-Legarrea P., de la Iglesia R., Crujeiras A. B., Pardo M., Casanueva F. F., Zulet M. A., Martinez J. A., Higher baseline irisin concentrations are associated with greater reductions in glycemia and insulinemia after weight loss in obese subjects. Nutrition and Diabetes 2014 4, article e110 10.1038/nutd.2014.7
32. Swick A., Orena S., O'Connor A., Irisin levels correlate with energy expenditure in a subgroup of humans with energy expenditure greater than predicted by fat free mass. Metabolism: Clinical and Experimental 2013 62 1070 1073 10.1016/j.metabol.2013.02.012
33. Hecksteden A., Wegmann M., Steffen A., Kraushaar J., Morsch A., Ruppenthal S., Kaestner L., Meyer T., Irisin and exercise training in humans-results from a randomized controlled training trial. BMC Medicine 2013 11, article 235
34. Timmons J. A., Baar K., Davidsen P. K., Atherton P. J., Is irisin a human exercise gene? Nature 2012 488 E9 E10 10.1038/nature11364
35. Kraemer R. R., Shockett P., Webb N. D., Shah U., Castracane V. D., A transient elevated irisin blood concentration in response to prolonged, moderate aerobic exercise in young men and women. Hormone and Metabolic Research 2014 46 2 150 154 10.1055/s-0033-1355381
36. Roberts M. D., Bayless D. S., Company J. M., Elevated skeletal muscle irisin precursor FNDC5 mRNA in obese OLETF rats. Metabolism: Clinical and Experimental 2013 62 8 1052 1056 10.1016/j.metabol.2013.02.002
37. Swick A., Orena S., O'Connor A., Irisin levels correlate with energy expenditure in a subgroup of humans with energy expenditure greater than predicted by fat free mass. Metabolism: Clinical and Experimental 2013 62 1070 1073 10.1016/j.metabol.2013.02.012
38. Myers M. G., Leibel R. L., Seeley R. J., Schwartz M. W., Obesity and leptin resistance: distinguishing cause from effect. Trends in Endocrinology and Metabolism 2010 21 11 643 651 2-s2.0-78049311283 10.1016/j.tem.2010.08.002
39. Virtanen K. A., Lidell M. E., Orava J., Heglind M., Westergren R., Niemi T., Taittonen M., Laine J., Savisto N.-J., Enerbäck S., Nuutila P., Functional brown adipose tissue in healthy adults. The New England Journal of Medicine 2009 360 15 1518 1525 2-s2.0-64349123664 10.1056/NEJMoa0808949
40. Zingaretti M. C., Crosta F., Vitali A., Guerrieri M., Frontini A., Cannon B., Nedergaard J., Cinti S., The presence of UCP1 demonstrates that metabolically active adipose tissue in the neck of adult humans truly represents brown adipose tissue. FASEB Journal 2009 23 9 3113 3120 2-s2.0-70349334680 10.1096/fj.09-133546